Literature DB >> 32297255

Bone metabolic biomarkers and bone mineral density in male patients with early-stage Alzheimer's disease.

Zhengping Pu1, Xiaoqing Tang2, Yu'e Fei3, Qingmei Hou4, Yong Lin1, Xianyou Zha1.   

Abstract

PURPOSE: Alzheimer's disease (AD), osteoporosis, and osteopenia are the most common diseases in older individuals and share some similar pathophysiological processes of degeneration. The aim of this study is to investigate the association between bone metabolic biomarkers, bone mineral density (BMD), and early-stage AD in men.
METHODS: Forty-two male early-stage AD patients and 40 age-matched healthy older volunteers were enrolled. Serum calcium, osteocalcin, 1,25(OH)2D3, urine deoxypyridinoline/creatinine (DPD/Cr) ratio, urine calcium/creatinine (Ca/Cr) ratio, and BMD were measured. The correlation between early-stage AD and bone quality was evaluated.
RESULTS: The urine DPD/Cr, urine Ca/Cr, and serum osteocalcin levels in the early-stage AD patients were significantly higher than those in the healthy control (HC) group (P < 0.05). The BMD data showed that the cortical and total BMD at 38% of the tibial length in the early-stage AD patients were lower than those in the HC group (P < 0.05). Furthermore, there was a negative correlation between the Montreal Cognitive Assessment score and serum osteocalcin or urine DPD/Cr levels. Abnormal urine DPD/Cr, urine Ca/Cr, and cortical BMD levels were independent risk factors in male patients with early-stage AD.
CONCLUSION: Bone metabolic biomarkers and BMD are closely associated with early-stage AD in male patients. Our data indicated that the measurement of bone metabolic biomarkers and BMD may provide an alternative approach for screening AD patients at the early stage.

Entities:  

Keywords:  Alzheimer’s disease; Bone metabolism; Bone mineral density; Osteoporosis

Year:  2020        PMID: 32297255     DOI: 10.1007/s41999-020-00289-z

Source DB:  PubMed          Journal:  Eur Geriatr Med        ISSN: 1878-7649            Impact factor:   1.710


  1 in total

Review 1.  Role of GPCR signaling and calcium dysregulation in Alzheimer's disease.

Authors:  Amal Chandra Mondal
Journal:  Mol Cell Neurosci       Date:  2019-10-23       Impact factor: 4.314

  1 in total
  6 in total

1.  Potential association of bone mineral density loss with cognitive impairment and central and peripheral amyloid-β changes: a cross-sectional study.

Authors:  Peng Zhang; Yi Zhou; Gang Chen; Jun Li; Bangjun Wang; Xinyan Lu
Journal:  BMC Musculoskelet Disord       Date:  2022-06-30       Impact factor: 2.562

2.  Effects of 6-Month Multimodal Physical Exercise Program on Bone Mineral Density, Fall Risk, Balance, and Gait in Patients with Alzheimer's Disease: A Controlled Clinical Trial.

Authors:  A Silvia Puente-González; M Carmen Sánchez-Sánchez; Eduardo J Fernández-Rodríguez; J Elicio Hernández-Xumet; Fausto J Barbero-Iglesias; Roberto Méndez-Sánchez
Journal:  Brain Sci       Date:  2021-01-06

3.  Alzheimer's Disease and Its Association With Bone Health: A Case-Control Study.

Authors:  Sameet Kumar; Aakash Chandnani; Norah H Aung; Simra Shahid; Dua Bukhari; Sania Shahzad; Besham Kumar; Sidra Memon
Journal:  Cureus       Date:  2021-03-08

4.  Protective effects of Forsythiae fructus and Cassiae semen water extract against memory deficits through the gut-microbiome-brain axis in an Alzheimer's disease model.

Authors:  Da Sol Kim; Ting Zhang; Sunmin Park
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

Review 5.  Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?

Authors:  Xun Gong; Hantao Zhang; Xiaoyan Liu; Yi Liu; Junlin Liu; Funmilayo O Fapohunda; Peng Lü; Kun Wang; Min Tang
Journal:  Front Aging Neurosci       Date:  2022-08-05       Impact factor: 5.702

6.  Short and medium-term effects of a multicomponent physical exercise program with a Mediterranean diet on bone mineral density, gait, balance, and fall risk for patients with Alzheimer disease: Randomized controlled clinical trial study protocol.

Authors:  Ana Silvia Puente-González; Felipe Sánchez-González; Juan Elicio Hernández-Xumet; María Carmen Sánchez-Sánchez; Fausto José Barbero-Iglesias; Roberto Méndez-Sánchez
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.